#JCLSpotlight: A text-based Health platform showed high interactivity & acceptability for tracking statin-associated muscle symptoms over time.
Read more from the study: https://ow.ly/ECuU50YEFyV
#JCLSpotlight: Elevated Lp(a) was found in 8.3% of the general population & up to 23.9% in those with ASCVD. Adding Lp(a) as a risk enhancer improved risk reclassification beyond HellenicSCOREII+ in two Greek cohorts.
Read more: https://ow.ly/jXMT50YCr6E
#JCLSpotlight: Poor sleep quality is linked to unfavorable lipid profiles, especially elevated sdLDL-C levels. Treating sleep quality as a modifiable lifestyle factor may help reduce lipid abnormalities and prevent CVD.
Read more: https://ow.ly/vayN50YBKQB
#JCLSpotlight | #NationalTriglyceridesDay
Rare late-onset FCS case highlights:
▪️ Delayed diagnosis → pancreatic insufficiency and malnutrition
▪️ Statin and pioglitazone withdrawal → improved clinical status
▪️ Volanesorsen → 74% triglyceride reduction from baseline
Read: https://ow.ly/7W9g50YzLPX
#JCLSpotlight from the March Issue: Obese patients with diabetes and CAD who achieved LDL-C <1.8 mmol/L showed greater coronary atheroma regression than nonobese patients.
Read more: https://ow.ly/7V3F50YzlU1
Spotlighting #LpaAwarenessDay with two recent JCL studies on Lp(a) testing:
1️⃣ Barriers & facilitators to Lp(a) testing: https://ow.ly/Gsmc50Yyich
2️⃣ QI study increases Lp(a) testing in outpatient cardiology clinic: https://ow.ly/exM350Yyicg
#KnowLpa
#JCLSpotlight: Two pediatric cases of early death from FH, alongside a systematic review of childhood and adolescent FH-related deaths, reveal diagnostic delays and inadequate treatment as common contributing factors.
Read more about the findings: https://ow.ly/oG7L50YxyGv
#JCLSpotlight: A rare variant in SCARB1 — p.(Thr378Met) — impairs SR-B1-mediated HDL uptake and is associated with elevated HDL-C levels, supporting SCARB1 as a candidate gene for genetic screening in patients with dyslipidemia.
Read more: https://ow.ly/yPhX50YwXV1
#JCLSpotlight: The BALANCE study shows olezarsen 80 mg reduced all-cause inpatient service utilization and improved the experience of patients with FCS after just one year of treatment.
Read more: https://ow.ly/AICF50Yw3ea
The Journal of Clinical Lipidology is growing!📈
Our 2025 CiteScore climbed to 6.8, a reflection of the high-quality research and dedicated community behind every issue.
#Lipidology #ClinicalResearch
The JCL February issue is live!📰
First in the #JCLSpotlight: A meta-analysis of 92 studies found carotid plaque in 23% of asymptomatic adults (18–65), rising from 5.2% (18–45) to 30.3% (50–65) and higher in men vs women.
Read more: https://ow.ly/qpxv50YqaC2
The NLA’s newest meta-analysis shows that in CVOTs of solely or predominantly primary prevention participants, each 1 mmol/L reduction in LDL-C was associated w/ a 30% RRR in 4-point MACE.
These findings support LDL-C lowering early in the life course: https://ow.ly/32o050YpGI4
On #WorldObesityDay, we invite you to explore the #JCLSpecialEdition on obesity, which brings together multidisciplinary insights for clinicians, researchers, educators, and public health leaders.
Read the issue: lipidjournal.com/issue/S1933-2874(26)X0002-2
#JCLSpecialEdition #Obesity
Diagnosis and management of CVD risk factors is an important aspect of an obesity management plan.
Evidence shows treatment with liraglutide, semaglutide, and/or bariatric surgery lowers CVD events and mortality.
Explore the full findings: https://ow.ly/LtnK50Yofyb
#JCLSpecialEdition #Obesity
A key characteristic of obesity is adipocytopathic atherogenic dyslipidemia. This review highlights the lipid specialist’s role in team-based obesity care to address cardiometabolic risk and improve long-term outcomes.
Read now: https://ow.ly/GOtQ50YmuEM
#JCLSpecialEdition #Obesity
Childhood obesity is a distinct condition with unique management needs. This review covers rising prevalence, genetic/environmental drivers, comorbidities & current treatments (IHBLT, metabolic surgery & pharmacotherapy).
Read now: https://ow.ly/AMmG50YlV5S
#JCLSpecialEdition #Obesity
Obesity management requires destigmatization and recognition as a chronic disease. This article highlights the role of GLP-1 RAs in achieving >10% weight loss with CV-kidney-metabolic benefits.
Read more: https://ow.ly/4QkW50Yl0Kv
NOW LIVE: #JCLSpecialEdition: Obesity as a Cardiometabolic Disease
How is obesity defined? This article evaluates the benefits and disadvantages of current and proposed measures to characterize obesity.
Read the review: https://ow.ly/xEBf50YkcVj
#JCLSpotlight: A BPA alert for patients with LDL-C ≥ 190 mg/dL increased statin use (39.4%→61.7%), reduced LDL-C by 84.1 mg/dL, and raised FH diagnoses (2.3%→6.0%). Electronic messaging may improve treatment and detection. #HeartMonth
Read more: https://ow.ly/cxPq50Yhatl
#JCLSpotlight: In a new analysis of the CLEAR Outcomes trial, adding lipid-modifying therapy after randomization did not impact the observed results of the trial.
Read more: https://ow.ly/Xi4P50YeBq2
#JCLSpotlight A pilot trial shows artichoke leaf extract reduced liver steatosis and size and improved body composition in patients with obesity and MASLD, while noting a significant transaminase increase.
🔗Read more: https://ow.ly/BXZA50Ye3e4
#JCLSpotlight: Elevated relative fat mass is strongly associated with a higher prevalence of sleep disorders in U.S. adults, highlighting adiposity as a modifiable factor in sleep health and prevention strategies.
Read more: https://ow.ly/HpRT50YbKoh
Last week, the NLA released its updated expert clinical consensus on familial hypercholesterolemia. The guidance covers refined diagnostic criteria, genetic testing, cascade screening, and updated management strategies, including therapies for HoFH and HeFH. #HeartMonth
🔗https://ow.ly/mm1w50Y90l7
#JCLSpotlight: Lomitapide effectively and safely reduced TG levels in FCS patients with prior pancreatitis over a nearly 3-year follow-up period. Results were consistent with open-label trial data despite a lower median dose, with no new safety signals observed.
🔗https://ow.ly/F0B650Y8X43
#JCLRoundtable: A European Perspective on Lipid Management & CV Health
Global experts Drs. Kausik Ray, Børge Nordestgaard, and P. Barton Duell discuss early LDL-C lowering, combination therapy, Lp(a) screening, FH, and what’s next in CV prevention.
Read the discussion: https://ow.ly/QJCH50Y544I
#JCLSpotlight: New research shows men and women have distinct inflammatory responses during long-term evolocumab therapy, highlighting the importance of sex-specific considerations in CV risk management and treatment monitoring.
Read more: https://ow.ly/Fa8B50Y3Utv
#JCLSpotlight: New research shows PCSK9 inhibitors and inclisiran significantly reduce visit-to-visit LDL-C variability vs standard therapy. Lower LDL-C variability was linked to fewer CV events, highlighting lipid stability as a key treatment goal.
Read more: https://ow.ly/qLkI50Y0Gbh
The January JCL issue is live!📘
#JCLSpotlight: A pooled analysis of phase 3 ODYSSEY studies shows that in patients with ASCVD (without prior ACS or stroke), alirocumab significantly reduced LDL-C vs placebo or ezetimibe.
Read more: https://ow.ly/QZrQ50Y0eyy
🚨Deadline Extended!🚨
You now have until January 12 at 11:59 PM ET to submit your abstract for the 2026 #NLASessions. Take advantage of this extension and make sure your research is part of the premier meeting in lipidology!
🔗Submit now: lipid.org/abstracts
#JCLSpotlight: High plasma Lp(a) is linked to increased IFN-γ–associated gene expression in classical monocytes and elevated CXCL10 in those without ASCVD, while chromatin accessibility remains unchanged across groups.
Read more: https://ow.ly/NENz50XKWcC
